Medtronic PLC (MDT)
21 Sep 2017
BRIEF-Medtronic announces clinical study to evaluate its Corevalve Evolut pro system in 'everyday' clinical practice
* Medtronic announces clinical study to evaluate the Corevalve Evolut pro system in 'everyday' clinical practice
* Medtronic announces FDA approval and U.S. launch of next generation spinal cord stimulator for chronic pain management Source text for Eikon: Further company coverage:
BRIEF-New five-year gender subset data from the Medtronic engage registry presented in viva late breaking trials
* New five-year gender subset data from the medtronic engage registry presented in viva late breaking trials
* Medtronic Plc - announced global launch of StealthStation ENT Source text for Eikon: Further company coverage:
* Medtronic announces voluntary recall of diabetes infusion sets
Sept 11 Medical device maker Medtronic Plc said on Monday it would recall certain infusion sets used with its insulin pumps by diabetes patients due to a component that could cause death in extreme cases.
Sept 11 Medtronic Plc on Monday said that it would recall certain infusion sets used with all its insulin pumps due to a discontinued component.
* Medtronic announces japanese regulatory approval for the IN.PACT Admiral drug-coated balloon
BRIEF-Medtronic launches long term clinical study program of infuse bone graft in 2 common spine procedures PLF, TLIF
* Medtronic launches long term clinical study program of infuse bone graft in two common spine procedures: PLF and TLIF
* Mazor Robotics and Medtronic enter next phase of strategic partnership; Medtronic to make a $40 million third tranche investment in Mazor
- M&A Deals Make The Market Interesting - Cramer's Mad Money (9/19/17)
- Your Daily Pharma Scoop: Nabriva's Further Potential, Allergan's IP Gimmick, Supernus's Positive Data
- I Was Right, There Was An Alpha Opportunity With My 15 Dividend Achievers
- Which 'Growthier' Dividend Stocks Look Attractive?
- A Shopping Trip Through My 80+ Stock Portfolio: Historic Dividend Yield Prices And More
- Can Abbott Top Its All-Time High?